Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Ending Cash Position : $5.99 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Merrimack Pharmaceuticals Ending Cash Position?

Merrimack Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2023 was $5.99 Mil.

Merrimack Pharmaceuticals's quarterly Ending Cash Position declined from Jun. 2023 ($10.13 Mil) to Sep. 2023 ($6.08 Mil) and declined from Sep. 2023 ($6.08 Mil) to Dec. 2023 ($5.99 Mil).

Merrimack Pharmaceuticals's annual Ending Cash Position increased from Dec. 2021 ($14.20 Mil) to Dec. 2022 ($19.44 Mil) but then declined from Dec. 2022 ($19.44 Mil) to Dec. 2023 ($5.99 Mil).

Merrimack Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for Merrimack Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merrimack Pharmaceuticals Ending Cash Position Chart

Merrimack Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

16.58

14.04

14.20

19.44

5.99

Merrimack Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															19.44	19.40	10.13	6.08	5.99

Merrimack Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Merrimack Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	19.439	+	-13.45
	=	5.99

Merrimack Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	6.083	+	-0.094
	=	5.99

Merrimack Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Merrimack Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merrimack Pharmaceuticals Inc (NAS:MACK) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Broadway, 14th Floor, Cambridge, MA, USA, 02142

Website

https://www.merrimack.com

Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.

Executives

Eric Andersen	director, other: See Remarks	1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404
Gary L Crocker	director, officer: President	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Noah G. Levy	director, other: See Remarks	60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165
Ana Radeljevic	director	2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467
Ulrik B. Nielsen	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Russell T Ray	director	2525 DUPONT DR, IRVINE CA 92612
Newtyn Capital Partners, Lp	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Ledo Capital, Llc	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Te Partners, Lp	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Partners, Lp	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Western Standard Partners Qp, L.p.	other: See Remarks	5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Partners Lp	other: See Remarks	5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Llc	other: See Remarks	5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036
Newtyn Management, Llc	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
22nw Gp, Inc.	10 percent owner, other: See Explanation of Responses	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107